Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kortenberg – page 12

1 955 clinical trials in Kortenberg, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kortenberg at a glance
1 955
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 955 trials in Kortenberg

Open in trial search

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Study of subcutaneous anifrolumab pharmacokinetics, pharmacodynamics and safety in children aged 5 to <18 years with systemic lupus erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trilaciclib dihydrochloride
  • Sponsor:Pharmacosmos A/S

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Asthma

Recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Engasertib to Evaluate Safety and Effectiveness in Adults with Moderate to Severe Hereditary Hemorrhagic Telangiectasia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Engasertib
  • Sponsor:Vaderis Therapeutics AG

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kortenberg

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. The trials aim to evaluate alternative treatment approaches for managing functional dyspepsia and related conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

The research explores on-demand medication use and alternative therapeutic options using alginate formulations, comparing their effectiveness with traditional tapering methods.

02 Digestive Health Studies

Clinical investigations examining treatment optimization for heartburn and reflux conditions. The research focuses on developing evidence-based approaches to reduce long-term medication dependency.

  • Symptom Management
  • Treatment Optimization
  • Medication Reduction Strategies

These trials aim to establish more effective approaches to managing digestive health while minimizing long-term medication use.

03 Primary Care Innovation

Primary care-focused research evaluating novel approaches to medication management in chronic conditions. The studies emphasize patient-centered strategies for reducing unnecessary long-term medication use.

  • Patient-Centered Care
  • Chronic Medicine Management
  • Evidence-Based Deprescribing

This research aims to transform primary care practices by establishing optimal deprescribing protocols for commonly used medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.